KCNE1 and long QT syndrome 1: To test our hypothesis that ML277 and R-L3 might serve as therapeutic agents in the treatment of some LQT-1 and LQT-5 mutation carriers, we first confirmed the efficacy of these compounds on IKS channels expressed in the absence and presence of KCNE1 subunits.